Search is Powered by Google
Cancer / Oncology News

Advalytix Announces Study Of Single Circulating Tumor Cells With The M. D. Anderson Cancer Center

Main Category: Cancer / Oncology
Also Included In: Breast Cancer;  Medical Devices / Diagnostics
Article Date: 12 Sep 2008 - 4:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

The Advalytix product team of Olympus is initiating a collaborative study with The University of Texas M. D. Anderson Cancer Center to characterize circulating tumor cells in breast cancer patients.

The study combines Advalytix's sensitive AmpliGrid molecular analysis platform, multiplex primer design, and integrated workflow to analyze expression of multiple target genes in single tumor cells.

"Using AmpliGrid, we plan to genetically fingerprint subpopulations of tumor cells with a convenient workflow," said Dr. James Reuben, Associate Professor at M. D. Anderson Cancer Center.

"The goal is to develop powerful tools to monitor the response to treatment, improve early detection, and personalize treatment for our patients," added Dr. Massimo Cristofanilli, M.D., Associate Professor in the Department of Breast Medical Oncology at M. D. Anderson.

The Advalytix AmpliGrid single-cell molecular analysis platform allows the M. D. Anderson team to measure heterogeneity by comparing the genetic profiles of individual tumor cells. Establishing the clinical relevance of heterogeneity requires studying a large number of clinical specimens. AmpliGrid meets these throughput requirements with a simple workflow that seamlessly integrates the steps needed for each clinical specimen, namely: cell sorting, sample preparation, and PCR.

About Breast Cancer

Breast cancer is the most common malignancy in women, and is the second leading cause of cancer death. A heterogeneous disease, the incidence of breast cancer has increased steadily since 1960. Each year 200,000 new cases of breast cancer are diagnosed, and over 40,000 patients die from the disease (data from http://www.thebreastcancersite.com).

About Advalytix

Advalytix is Olympus' worldwide competence centre for cell-based molecular biology, with a focus on single cell molecular diagnostics, and the miniaturization of diagnostic and biological tests for research and development. Advalytix products uniquely link imaging technologies such as microscopy with nucleic acid analysis, enabling turnkey solutions with optimized instruments and reagents.

Advalytix




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Urology
ADHD Autism Diabetes

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Shocking Pictures To Appear On Cigarette Packets In UK On 1st October
27 Sep 2008
The UK's ten million Smokers may see pictures of rotting teeth, throat cancer, and indications of male impotence (erectile dysfunction) on cigarette packets they buy at the beginning of October...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...